37524-08-6

Upstream product

• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 82819-54-3 methyl 2-nitro-3-hydroxy-4-aminobenzoate 
• 56709-80-9 methyl 2,4-dinitro-3-hydroxybenzoate 
• 37524-01-9 methyl 4-bromo-2-nitro-3-hydroxybenzoate 

Downstream Products

• 81914-64-9 N-(2-nitro-3-hydroxy-4-bromobenzoyl)tris(hydroxymethyl)methylamine 
• 99573-17-8 methyl 3-(benzyloxy)-4-bromo-2-nitrobenzoate 
• 37524-01-9 methyl 4-bromo-2-nitro-3-hydroxybenzoate 
• 39978-92-2 2-amino-4-bromo-3-hydroxy-benzoic acid 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS

The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF

Provided are compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Benzoxazole carboxamides for treating CINV and IBS-D

Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.

SYNTHESIS OF ACTINOMYCIN ANALOGS. XII. 4,6-DIACETYLAMINOCINNABARIC ACID AND ITS DERIVATIVES

The selective reduction of methyl 2,4-dinitro-3-hydroxybenzoate gave methyl 2-nitro-3-hydroxy-4-aminobenzoate.The latter was used to synthesize 4,6-diacetylaminocinnabaric acid, its dimethyl ester, and the dihydrochloride of 4,6-diacetylaminocinnabaryl-bi